Abstract

Juvenile dermatomyositis is a chronic and rare autoimmune disorder classified into the spectrum of idiopathic inflammatory myopathies. Although this entity is mainly characterized by the presence of pathognomonic cutaneous lesions and proximal muscle weakness, the clinical manifestation can be highly heterogeneous; thus, diagnosis might be challenging. Current treatment recommendations for juvenile dermatomyositis, based mainly upon case series, include the use of corticosteroids, immunomodulatory, and immunosuppressive agents. Recently, several specific autoantibodies have been shown to be associated with distinct clinical phenotypes of classic dermatomyositis. There is a need to further evaluate their relevance in the formation of various clinical features. Furthermore, while providing more personalized treatment strategies, one should consider diversity of autoantibody-related subgroups of juvenile dermatomyositis.

Highlights

  • Juvenile dermatomyositis (JDM) is a chronic, systemic, autoimmune disease belonging to the so called connective tissue disorders

  • JDM is characterized by the presence of pathognomonic cutaneous lesions and proximal muscle weakness

  • The paraneoplastic phenomenon has very rarely been noted in pediatric patients, and the current data are limited to a few cases in the literature [6, 7]

Read more

Summary

Introduction

Juvenile dermatomyositis (JDM) is a chronic, systemic, autoimmune disease belonging to the so called connective tissue disorders. It is the most common inflammatory myopathy in children, accounting for approximately 85% of cases. In adults, elevated serum levels of muscle enzymes, including creatine kinase (CK), transaminases, lactate dehydrogenase (LDH), and aldolase, play an important role in the diagnosis and severity assessment of DM. Those enzymes proved to be weakly correlated with disease severity in JDM [3,4,5].

Materials and Methods
Myositis-Specific Autoantibodies
Conclusions
Findings
Conflicts of Interest
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call